首页> 美国卫生研究院文献>Nucleic Acids Research >Human mitochondrial uracil-DNA glycosylase preform (UNG1) is processed to two forms one of which is resistant to inhibition by AP sites.
【2h】

Human mitochondrial uracil-DNA glycosylase preform (UNG1) is processed to two forms one of which is resistant to inhibition by AP sites.

机译:人线粒体尿嘧啶-DNA糖基化酶预制棒(UNG1)被加工成两种形式其中一种可以抵抗AP位点的抑制。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The preform of human mitochondrial uracil-DNA glycosylase (UNG1) contains 35 N-terminal residues required for mitochondrial targeting. We have examined processing of human UNG1 expressed in insect cells and processing in vitro by human mitochondrial extracts . In insect cells we detected a major processed form lacking 29 of the 35 unique N-terminal residues (UNG1Delta29, 31 kDa) and two minor forms lacking the 75 and 77 N-terminal residues, respectively (UNG1Delta75 and UNG1Delta77, 26 kDa). Purified UNG1Delta29 was effectively cleaved in vitro to a fully active 26 kDa form by human mitochondrial extracts. Furthermore, endogenous forms of 31 and 26 kDa were also observed in HeLa mitochondrial extracts. The sequences at the cleavage sites, as identified by peptide sequencing, were compatible with the known specificity of mitochondrial processing peptidase (MPP). However, in vitro cleavage of UNG1Delta29 by mitochondrial extracts did not require divalent cations and was stimulated by EDTA, indicating the involvement of a processing peptidase distinct from MPP at the second site. Interestingly, while UNG1Delta29 generally has the typical properties reported for other uracil-DNA glycosylases, it is not inhibited by apurinic/apyrimidinic sites. Our results indicate that the preform of human mitochondrial uracil-DNA glycosylase is processed to distinctly different forms lacking 29 or 75/77 N-terminal residues, respectively.
机译:人线粒体尿嘧啶-DNA糖基化酶(UNG1)的预成型品包含35个N-端线粒体靶向所需的残基。我们研究了在昆虫细胞中表达的人UNG1的加工和在体外由人线粒体提取物的加工。在昆虫细胞中,我们检测到主要加工形式缺少35个独特的N末端残基中的29个(UNG1Delta29,31 kDa),而两个次要形式分别缺少75和77个N末端残基(UNG1Delta75和UNG1Delta77,26 kDa)。纯化的UNG1Delta29在体外被人线粒体提取物有效切割为完全活性的26 kDa形式。此外,在HeLa线粒体提取物中还观察到内源形式的31和26 kDa。如通过肽测序所鉴定的,在切割位点的序列与线粒体加工肽酶(MPP)的已知特异性相容。但是,线粒体提取物对UNG1Delta29的体外切割不需要二价阳离子,并且受到EDTA的刺激,表明第二个位点参与了不同于MPP的加工肽酶的参与。有趣的是,虽然UNG1Delta29通常具有其他尿嘧啶-DNA糖基化酶的典型特性,但不受嘌呤/嘧啶基位点的抑制。我们的结果表明,人线粒体尿嘧啶-DNA糖基化酶的预制棒被加工成明显不同的形式,分别缺少29或75/77 N端残基。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号